|
Dr. M. Javad Aman is a molecular immunologist with over 30 years of experience in immunology, microbiology, and the development of vaccines and immunotherapeutics for infectious diseases. He earned his Ph.D. in molecular immunology from Johannes Wolfgang University in Mainz, Germany. Following postdoctoral research at the National Institutes of Health (NIH) and the University of Virginia, he served as a Principal Investigator at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), focusing on vaccines for bacterial toxins and viral hemorrhagic fever viruses.
In 2005, Dr. Aman founded Integrated BioTherapeutics (IBT), a biotechnology company dedicated to discovering vaccines and immunotherapeutics for emerging infectious diseases. Under his leadership, IBT has become a clinical-stage company, securing over $120 million in non-dilutive funding. In 2023, he spun off AbVacc from IBT to concentrate on structure-guided design of vaccines and immunotherapeutics.
Dr. Aman recently shared vision for the company's future:
"The company reorganization marks a pivotal moment in our journey, empowering us to better serve our clients’ evolving needs. This transition reinforces our dedication to innovation, ensuring that the company continues to deliver exceptional CRO services to our partners."
|
Loading ....
